December 22, 2017 Qualitative Development and Cognitive Evaluation of the Symptoms of Major Depressive Disorder (S-MDD), A Consortium-Developed Patient Reported Outcome Measure
December 18, 2017 C-Path receives COA qualification from FDA for the Symptoms of Major Depressive Disorder Scale (SMDDS) Tucson, AZ – December 18, 2017 Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium annou
December 8, 2017 Characterizing Disease Progression for Parkinson’s Disease to implement efficient trial designs
December 8, 2017 Model-Informed Biomarker Qualification: Alzheimer and Parkinson Disease Imaging Biomarkers
December 4, 2017 C-Path and FARA announce collaborative data aggregation project for Friedreich’s ataxia Tucson, AZ, and Downingtown, PA — December 4, 2017 — Critical Path Institute‘s (C-Path) Data Colla
December 1, 2017 Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy
November 25, 2017 Chronic Pulmonary Insufficiency of Prematurity: Developing Optimal Endpoints for Drug Development
November 16, 2017 FDA CDER Regulatory Science: The Importance of Partnership and Consortia Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research within the United States Food and Drug Administration,